RAVIKUMAR KANNEGANTI: Open Payments
NPI 1679643191 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,773 in 94 payments from 14 companies in 2025. Trend: 2023 $2,517 · 2024 $1,560 · 2025 $1,773
Food & beverage: $1,773
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $534 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $260 |
| Otsuka America Pharmaceutical, Inc. | 12 | $206 |
| E.R. Squibb & Sons, L.L.C. | 10 | $201 |
| Teva Pharmaceuticals USA, Inc. | 13 | $194 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Tris Pharma Inc | 4 | $66 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Corium, LLC | 6 | $50 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
Products named: INGREZZA, CAPLYTA, COBENFY, REXULTI, UZEDY, AUSTEDO XR, Auvelity, Jornay PM.
Industry payments across TX — which companies pay providers there.
